Complement 5a receptor mediates angiotensin II-induced cardiac inflammation and remodeling

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 6, 2014, Pages 1240-1248

  Zhang, Congcong ^a   Li, Yulin ^a   Wang, Chunxiao ^a   Wu, Yina ^a   Cui, Wei ^a   Miwa, Takashi ^b   Sato, Sayaka ^b   Li, Huihua ^a   Song, Wen Chao ^b   Du, Jie ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

angiotensin II; complement C5a; complement system proteins; hypertension; inflammation

Indexed keywords

ANGIOTENSIN II; CD11B ANTIGEN; CD45 ANTIGEN; CELL ADHESION MOLECULE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5A RECEPTOR; CYTOKINE; DRUG ANTIBODY; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C5; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CARDIAC REMODELING; CARDITIS; CELL INFILTRATION; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; COMPLEMENT DEFICIENCY; COMPLEMENT DEPOSITION; COMPLEMENT INHIBITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; EXPERIMENTAL HYPERTENSION; HEART DISEASE; HEART INJURY; HEART PROTECTION; HUMAN; MACROPHAGE MIGRATION; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

ANGIOTENSIN II; COMPLEMENT C5A; COMPLEMENT SYSTEM PROTEINS; HYPERTENSION; INFLAMMATION;

ANGIOTENSIN II; ANIMALS; CELL ADHESION; CELL MOVEMENT; CELLS, CULTURED; COMPLEMENT ACTIVATION; HUMANS; HYPERTENSION; MACROPHAGES; MICE; MICE, INBRED C57BL; MYOCARDITIS; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, COMPLEMENT; VENTRICULAR REMODELING;

EID: 84901489226     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.303120     Document Type: Article

References (40)

1. McCormack T, Krause T, O'Flynn N. Management of hypertension in adults in primary care: NICE guideline. Br J Gen Pract. 2012;62:163-164.
2. Susic D, Frohlich ED. Hypertensive cardiovascular and renal disease and target organ damage: lessons from animal models. Cardiorenal Med. 2011;1:139-146.
3. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest. 2007;117:568-575. (Pubitemid 46348511)
4. Burlew BS, Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz. 2002;27:92-98. (Pubitemid 34309394)
5. Jia L, Li Y, Xiao C, Du J. Angiotensin II induces inflammation leading to cardiac remodeling. Front Biosci (Landmark Ed). 2012;17:221-231.
6. Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344: 1058-1066.
7. Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun. 2010;34:J276-J286.
8. Walport MJ. Complement. Second of two parts. N Engl J Med. 2001;344: 1140-1144.
9. Engström G, Hedblad B, Berglund G, Janzon L, Lindgärde F. Plasma levels of complement C3 is associated with development of hypertension: a longitudinal cohort study. J Hum Hypertens. 2007;21:276-282. (Pubitemid 46443589)
10. Gan W, Wu J, Lu L, Xiao X, Huang H, Wang F, Zhu J, Sun L, Liu G, Pan Y, Li H, Lin X, Chen Y. Associations of CFH polymorphisms and CFHR1- CFHR3 deletion with blood pressure and hypertension in Chinese population. PLoS One. 2012;7:e42010.
11. Shagdarsuren E, Wellner M, Braesen JH, Park JK, Fiebeler A, Henke N, Dechend R, Gratze P, Luft FC, Muller DN. Complement activation in angiotensin II-induced organ damage. Circ Res. 2005;97:716-724. (Pubitemid 41416341)
12. -/- mice. FASEB J. 2011;25:2447-2455.
13. Shagdarsuren E, Bidzhekov K, Mause SF, Simsekyilmaz S, Polakowski T, Hawlisch H, Gessner JE, Zernecke A, Weber C. C5a receptor targeting in neointima formation after arterial injury in atherosclerosis-prone mice. Circulation. 2010;122:1026-1036.
14. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, Lambris JD, Warner RL, Flierl MA, Hoesel LM, Gebhard F, Younger JG, Drouin SM, Wetsel RA, Ward PA. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med. 2006;12:682-687. (Pubitemid 43865238)
15. Burwick RM, Fichorova RN, Dawood HY, Yamamoto HS, Feinberg BB. Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension. 2013;62:1040-1045.
16. Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis. 2010;30:245-257.
17. Li Y, Zhang C, Wu Y, Han Y, Cui W, Jia L, Cai L, Cheng J, Li H, Du J. Interleukin-12p35 deletion promotes CD4 T-cell-dependent macrophage differentiation and enhances angiotensin II-Induced cardiac fibrosis. Arterioscler Thromb Vasc Biol. 2012;32:1662-1674.
18. Han YL, Li YL, Jia LX, Cheng JZ, Qi YF, Zhang HJ, Du J. Reciprocal interaction between macrophages and T cells stimulates IFN-γ and MCP-1 production in Ang II-induced cardiac inflammation and fibrosis. PLoS One. 2012;7:e35506.
19. Ma F, Li Y, Jia L, Han Y, Cheng J, Li H, Qi Y, Du J. Macrophagestimulated cardiac fibroblast production of IL-6 is essential for TGF β/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS One. 2012;7:e35144.
20. Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20:34-50.
21. Pinckard RN, Olson MS, Giclas PC, Terry R, Boyer JT, O'Rourke RA. Consumption of classical complement components by heart subcellular membranes In vitro and in patients after acute myocardial infarction. J Clin Invest. 1975;56:740-750.
22. Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med. 1984;160:1558-1578. (Pubitemid 15220783)
23. Wu J, Wu YQ, Ricklin D, Janssen BJ, Lambris JD, Gros P. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol. 2009;10:728-733.
24. Noris M, Remuzzi G. Overview of complement activation and regulation. Semin Nephrol. 2013;33:479-492.
25. Luft FC, Dechend R, Müller DN. Immune mechanisms in angiotensin II-induced target-organ damage. Ann Med. 2012;44 Suppl 1:S49-S54.
26. Jia LX, Qi GM, Liu O, Li TT, Yang M, Cui W, Zhang WM, Qi YF, Du J. Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis. Cardiovasc Drugs Ther. 2013;27:521-530.
27. de Vries B, Walter SJ, Peutz-Kootstra CJ, Wolfs TG, van Heurn LW, Buurman WA. The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. Am J Pathol. 2004;165:1677-1688. (Pubitemid 39435166)
28. Peng Q, Li K, Smyth LA, Xing G, Wang N, Meader L, Lu B, Sacks SH, Zhou W. C3a and C5a promote renal ischemia-reperfusion injury. J Am Soc Nephrol. 2012;23:1474-1485.
29. Ehrnthaller C, Ignatius A, Gebhard F, Huber-Lang M. New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med. 2011;17:317-329.
30. Thurman JM, Ljubanović D, Royer PA, Kraus DM, Molina H, Barry NP, Proctor G, Levi M, Holers VM. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest. 2006;116:357-368. (Pubitemid 43228352)
31. Jokiranta TS, Cheng ZZ, Seeberger H, Jòzsi M, Heinen S, Noris M, Remuzzi G, Ormsby R, Gordon DL, Meri S, Hellwage J, Zipfel PF. Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. Am J Pathol. 2005;167:1173-1181. (Pubitemid 41416267)
32. Jia LX, Qi GM, Liu O, Li TT, Yang M, Cui W, Zhang WM, Qi YF, Du J. Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis. Cardiovasc Drugs Ther. 2013;27:521-530.
33. Wagner DD. New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol. 2005;25:1321-1324. (Pubitemid 40923346)
34. Peerschke EI, Yin W, Grigg SE, Ghebrehiwet B. Blood platelets activate the classical pathway of human complement. J Thromb Haemost. 2006;4:2035-2042. (Pubitemid 44226786)
35. Hamad OA, Ekdahl KN, Nilsson PH, Andersson J, Magotti P, Lambris JD, Nilsson B. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J Thromb Haemost. 2008;6:1413-1421. (Pubitemid 352016323)
36. Del Conde I, Crúz MA, Zhang H, López JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med. 2005;201:871-879. (Pubitemid 40524457)
37. Iyer A, Woodruff TM, Wu MC, Stylianou C, Reid RC, Fairlie DP, Taylor SM, Brown L. Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol. 2011;58:479-486.
38. Meri S. Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med. 2013;24:496-502.
39. Speidl WS, Kastl SP, Huber K, Wojta J. Complement in atherosclerosis: friend or foe? J Thromb Haemost. 2011;9:428-440.
40. Damman J, Daha MR, van Son WJ, Leuvenink HG, Ploeg RJ, Seelen MA. Crosstalk between complement and Toll-like receptor activation in relation to donor brain death and renal ischemia-reperfusion injury. Am J Transplant. 2011;11:660-669.